Hirsutism in Women

 

Am Fam Physician. 2019 Aug 1;100(3):168-175.

  Patient information: A handout on this topic is available at https://familydoctor.org/condition/hirsutism.

Author disclosure: No relevant financial affiliations.

Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female. It is often a sign of excessive androgen levels. Although many conditions can lead to hirsutism, polycystic ovary syndrome and idiopathic hyperandrogenism account for more than 85% of cases. Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumors, medications, hyperprolactinemia, thyroid disorders, and Cushing syndrome. Women with an abnormal hirsutism score based on the Ferriman-Gallwey scoring system should be evaluated for elevated androgen levels. Women with rapid onset of hirsutism over a few months or signs of virilization are at high risk of having an androgen-secreting tumor. Hirsutism may be treated with pharmacologic agents and/or hair removal. Recommended pharmacologic therapies include combined oral contraceptives, finasteride, spironolactone, and topical eflornithine. Because of the length of the hair growth cycle, therapies should be tried for at least six months before switching treatments. Hair removal methods such as shaving, waxing, and plucking may be effective, but their effects are temporary. Photoepilation and electrolysis are somewhat effective for long-term hair removal but are expensive.

Hirsutism is excessive growth of terminal hair in a typical male pattern in a female. It is typically a sign of excessive androgen levels. Hirsutism has been reported in 5% to 15% of women and is often associated with decreased quality of life and significant psychological stress.15 Hirsutism should be differentiated from hypertrichosis, which is increased growth—typically of vellus hair—in a generalized nonsexual distribution that is independent of androgens, although hyperandrogenism can exacerbate the condition.6

 Enlarge     Print

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingComments

Women with an abnormal Ferriman-Gallwey score should be tested for elevated androgen levels.6,14,22

C

Based on expert opinion and consensus guidelines in the absence of clinical trials

Combined oral contraceptives are first-line therapy for women with hirsutism who are not trying to conceive and in whom cosmetic measures are ineffective.6,22,25,26,32

B

Based on inconsistent or limited-quality evidence from RCTs showing improvement in patient-reported hirsutism

If patient-important hirsutism persists after six months of therapy with combined oral contraceptives, the addition of an antiandrogen should be considered.6,22,25,27,28,33

A

Based on consistent evidence from RCTs showing improvement in patient-reported hirsutism

Gonadotropin-releasing hormone agonists should be avoided for the treatment of hirsutism except in patients with severe hyperandrogenism, in whom combined oral contraceptives and antiandrogens are ineffective.6,34

C

Based on expert opinion and consensus guidelines in the absence of clinical trials

Insulin-lowering drugs are not recommended to treat hirsutism.6,25,30

B

Based on limited-quality patient-oriented evidence from RCTs showing no improvement in patient-reported hirsutism

Photoepilation is the preferred treatment for most patients who desire permanent hair removal. Those with blonde or white hair should use electrolysis.6,36

B

Based on limited-quality patient-oriented evidence from RCTs showing improvement in patient-reported hirsutism


RCT = randomized controlled trial.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingComments

Women with an abnormal Ferriman-Gallwey score should be tested for elevated androgen levels.6,14,22

C

Based on expert opinion and consensus guidelines in the absence of clinical trials

Combined oral contraceptives are first-line therapy for women with hirsutism who are not trying to conceive and in whom cosmetic measures are ineffective.6,22,25,26,32

B

Based on inconsistent or limited-quality evidence from RCTs showing improvement in patient-reported hirsutism

If patient-important hirsutism persists after six months of therapy with combined oral contraceptives, the addition of an antiandrogen should be considered.6,22,25,27,28,33

A

Based on consistent evidence from RCTs showing improvement in patient-reported hirsutism

Gonadotropin-releasing hormone agonists should be avoided for the treatment of hirsutism except in patients with severe hyperandrogenism, in whom combined oral contraceptives and antiandrogens are ineffective.6,34

C

Based on expert opinion and consensus guidelines in the absence of clinical trials

Insulin-lowering drugs are not recommended to treat hirsutism.6,25,30

B

Based on limited-quality patient-oriented evidence from RCTs showing no improvement in patient-reported hirsutism

Photoepilation is the preferred treatment for most patients who desire permanent hair removal. Those with blonde or white hair should use electrolysis.6,36

B

Based on limited-quality patient-oriented evidence from RCTs showing improvement in patient-reported hirsutism


RCT = randomized controlled trial.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

Physiology

Structurally, there are three types of hairs: lanugo, which is soft hair on the skin of the fetus that disappears in utero or in the first few weeks of life; vellus hairs, which are soft, small, and nonpigmented; and terminal hairs, which are longer, larger, coarser, and pigmented. The hair follicle cycles through three phases: anagen, a period of rapid growth; catagen, a period of involution; and telogen, a period of rest and shedding of hair.7 The duration of the anagen phase and rate of growth determine the length of hair and vary by type of hair and body region. The anagen cycle of facial hair is about four months; therefore, it takes about six months to note any change after an intervention and nine months to see maximal change.

Hair growth is influenced by several local and systemic factors, including cytokines, growth factors, and sex steroids.8 Hair type and distribution are dependent on androgens that cause transformation of vellus hairs to terminal hairs. Androgens affect hair growth broadly, and there are only a limited number of androgen-independent areas (e.g., eyelashes, eyebrows, some scalp follicles).9,10 Androgens have a paradoxical response on the face and scalp: stimulating beard growth and inhibiting scalp hair growth lead to androgenic alopecia (male pattern baldness). Thyroid hormones, insulin resistance, and specific genes also influence hair growth.

Diagnosis

Hirsutism is a clinical diagnosis, and prevalence depends on the diagnostic criteria used. Hirsutism is commonly diagnosed using the modified Ferriman-Gallwey scoring system consisting of nine androgen-sensitive body areas11,12 (Figure 113). Cutoff scores vary by race and ethnicity: scores of 8 or greater are considered hirsutism in British and U.S. black and white women; 9 or greater in Mediterranean, Hispanic, and Middle Eastern women; 6 or greater in South American women; and 2 or greater in Asian women.6 Scores up to 15 indicate mild hirsutism, whereas those greater than 25 indicate severe hirsutism. Limitations of this scoring system include its subjective nature and inability to account for locally high scores or previous cosmetic treatments. The Endocrine Society recommends treating patient-important hirsutism, which is unwanted sexual hair growth of sufficient extent to cause patient distress.6

FIGURE 1.

The Ferriman-Gallwey score for hirsutism. A score of 1 to 4 is given for nine areas of the body. A total score less than 8 is considered normal; a score of 8 to 15 indicates mild hirsutism; and a score greater than 15 indicates moderate to severe hirsutism. A score of 0 indicates absence of terminal hair.

Illustration by Renee Cannon

Reprinted with permission from Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):374.


FIGURE 1.

The Ferriman-Gallwey score for hirsutism. A score of 1 to 4 is given for nine areas of the body. A total score less than 8 is considered normal; a score of 8 to 15 indicates mild hirsutism; and a score greater than 15 indicates moderate to severe hirsutism. A score of 0 indicates absence of terminal hair.

Illustration by Renee Cannon

Reprinted with permission from Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):374.

Causes

Most cases of hirsutism are due to functional causes of excess androgens. The causes of hirsutism and their diagnostic clues are listed in Table 1.6,1315

 Enlarge     Print

TABLE 1.

Causes of Hirsutism and Their Diagnostic Clues

DiagnosisPercentage of casesHistorical and clinical clues

Polycystic ovary syndrome

71

Acanthosis nigricans Acne Central obesity Infertility Insulin resistance Menstrual dysfunction Normal or slightly elevated androgen levels Polycystic ovary morphology on ultrasonography

Idiopathic hyperandrogenism

15

Elevated androgen levels No other secondary cause Normal menses Normal ovarian morphology on ultrasonography

Idiopathic hirsutism

10

No other secondary causes Normal androgen levels Normal menses Normal ovarian morphology on ultrasonography

Nonclassic congenital adrenal hyperplasia

3

Elevated 17-hydroxyprogesterone level before and after corticotropin stimulation test Family history of adrenal hyperplasia High-risk ethnic group (e.g., Ashkenazi Jews, Hispanics, Slavic people) Infertility Menstrual dysfunction (including primary amenorrhea)

Androgen-secreting tumors

0.3

Elevated testosterone or dehydroepiandrosterone sulfate level Palpable abdominal or pelvic mass Progression of hirsutism despite treatment Rapid onset of hirsutism Small masses may have indolent presentation Virilization (e.g., clitoromegaly, increased muscularity, deepened voice)

Iatrogenic hirsutism

Uncommon; prevalence not well defined

History of anabolic-androgenic steroid use Use of topical testosterone in a partner Use of valproic acid (Depakene)

Acromegaly

Rarely presents with isolated hirsutism

Coarse facial features Deepened voice Enlargement of nose and ears Frontal bossing Hyperhidrosis Increased hand and foot size Mandibular enlargement with increased interdental spacing

Cushing syndrome

Rarely presents with isolated hirsutism

Acne Central obesity Elevated 24-hour urinary free cortisol level Hypertension Impaired glucose tolerance Moon facies Proximal muscle weakness Purple skin striae

Hyperprolactinemia

Rarely presents with isolated hirsutism

Amenorrhea Galactorrhea Infertility

Thyroid disorders

Rarely present with isolated hirsutism

Menstrual dysfunction Thyroid dysfunction Hyperthyroidism: exophthalmos, goiter, heat intolerance, hyperactivity, palpitations, sleep disturbance, tremor, weight loss Hypothyroidism: cold intolerance, difficulty concentrating, dry skin, fatigue, hair loss, myxedema, weight gain


Adapted with permission from Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):375, with additional information from references 6, 14, and 15.

TABLE 1.

Causes of Hirsutism and Their Diagnostic Clues

DiagnosisPercentage of casesHistorical and clinical clues

Polycystic ovary syndrome

71

Acanthosis nigricans Acne Central obesity Infertility Insulin resistance Menstrual dysfunction Normal or slightly elevated androgen levels Polycystic ovary morphology on ultrasonography

Idiopathic hyperandrogenism

15

Elevated androgen levels No other secondary cause Normal menses Normal ovarian morphology on ultrasonography

Idiopathic hirsutism

10

No other secondary causes Normal androgen levels Normal menses Normal ovarian morphology on ultrasonography

Nonclassic congenital adrenal hyperplasia

3

Elevated 17-hydroxyprogesterone level before and after corticotropin stimulation test Family history of adrenal hyperplasia High-risk ethnic group (e.g., Ashkenazi Jews, Hispanics, Slavic people) Infertility Menstrual dysfunction (including primary amenorrhea)

Androgen-secreting tumors

0.3

Elevated testosterone or dehydroepiandrosterone sulfate level Palpable abdominal or pelvic mass Progression of hirsutism despite treatment Rapid onset of hirsutism Small masses may have indolent presentation Virilization (e.g., clitoromegaly, increased muscularity, deepened voice)

Iatrogenic hirsutism

Uncommon; prevalence not well defined

History of anabolic-androgenic steroid use Use of topical testosterone in a partner Use of valproic acid (Depakene)

Acromegaly

Rarely presents with isolated hirsutism

Coarse facial features Deepened voice Enlargement of nose and ears Frontal bossing Hyperhidrosis Increased hand and foot size Mandibular enlargement with increased interdental spacing

Cushing syndrome

Rarely presents with isolated hirsutism

Acne Central obesity Elevated 24-hour urinary free cortisol level Hypertension Impaired glucose tolerance Moon facies Proximal muscle weakness Purple skin striae

Hyperprolactinemia

Rarely presents with isolated hirsutism

Amenorrhea Galactorrhea Infertility

Thyroid disorders

Rarely present with isolated hirsutism

Menstrual dysfunction Thyroid dysfunction Hyperthyroidism: exophthalmos, goiter, heat intolerance, hyperactivity, palpitations, sleep disturbance, tremor, weight loss Hypothyroidism: cold intolerance, difficulty concentrating, dry skin, fatigue, hair loss, myxedema, weight gain


Adapted with permission from Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):375, with additional information from references 6, 14, and 15.

POLYCYSTIC OVARY SYNDROME

Polycystic ovary syndrome (PCOS) is the most common cause of hirsutism, accounting for more than 70% of cases.14 PCOS is defined by the presence of at least two of the following criteria: chronic anovulation, clinical or biologic hyperandrogenism, and polycystic ovaries.16 Additional symptoms include obesity, acne, alopecia, insulin resistance, infertility, and acanthosis nigricans. Androgen levels may be normal or mildly elevated. Hyperinsulinemia affects more than one-half of women with PCOS, triggering an increase in gonadotropin-releasing hormone pulse frequency. The subsequent increase in gonadotropin-releasing hormones triggers increased production of ovarian and adrenal androgens while the production of sex hormone–binding globulin in the liver decreases, resulting in an increased amount of biologically active free testosterone in the serum.15

IDIOPATHIC HYPERANDROGENISM

Idiopathic hyperandrogenism accounts for approximately 15% of hirsutism cases.14 It is characterized by normal menses, normal ovaries on ultrasonography, elevated androgen levels, and no secondary causes.

IDIOPATHIC HIRSUTISM

Idiopathic hirsutism is a diagnosis of exclusion that accounts for approximately 10% of cases in women who have normal menses, normal ovarian morphology, and normal levels of serum androgens.14 Data suggest that approximately one-half of women with mild hirsutism have idiopathic hirsutism.17

ADRENAL HYPERPLASIA

Adrenal hyperplasia is inherited in an autosomal recessive pattern and is due to deficiency of one of the enzymes involved in adrenal steroid hormone synthesis, causing precursors to be shunted to the androgen pathway. Congenital adrenal hyperplasia is typically diagnosed at birth and is often associated with ambiguous genitalia and androgen excess. Nonclassic congenital adrenal hyperplasia is a milder form presenting in the peripubertal period with hirsutism and primary amenorrhea or infertility. The most common deficiency in people with nonclassic congenital adrenal hyperplasia is 21-hydroxylase deficiency resulting in elevated levels of 17-hydroxyprogesterone. Adrenal hyperplasia is more common in certain high-risk groups, such as Ashkenazi Jews, Hispanics, and Slavic people.18 Women with hirsutism who are at higher risk of adrenal hyperplasia because of their race or ethnicity should be screened by measuring early morning follicular phase 17-hydroxyprogesterone, even if serum total and free testosterone levels are normal.6

ANDROGEN-SECRETING TUMORS

Androgen-secreting tumors are a rare cause of hirsutism, can be ovarian or adrenal in origin, and are malignant in more than 50% of cases.6 The typical presentation is a more rapid onset of hirsutism (within a few months vs. several months to a year or more with other causes) with other androgenic findings or virilization (e.g., increased muscularity, deepening of the voice, breast atrophy, male pattern baldness, clitoromegaly). Small tumors can have more indolent presentations. The physical examination may reveal abdominal or pelvic masses; if they are adrenal in origin there will typically be associated hypercortisolemia and elevated dehydroepiandrosterone and dehydroepiandrosterone sulfate (DHEAS) levels, leading to Cushing syndrome.

OTHER CAUSES

Other endocrine disorders such as hyperprolactinemia, thyroid disorders, acromegaly, and Cushing syndrome may be associated with hirsutism but rarely present with isolated hirsutism. Iatrogenic hirsutism can be caused by the use of certain medications, especially cyclosporine (Sandimmune), danazol, diazoxide, glucocorticoids, minoxidil, testosterone, and other anabolic steroids.19,20

Evaluation

Hirsutism is most often due to benign conditions, although it can be a sign of an underlying hyperandrogenic disorder that requires specific treatment and has implications for reproduction, adverse health effects, or even life-threatening neoplasia.6 Figure 2 illustrates a suggested evaluation for hirsutism.6,13,14,21 A detailed history and physical examination are essential. The history should include family history of hyperandrogenism, menstrual history, description of the onset of hirsutism, androgenic medications (including topical use by a partner), and history of cosmetic treatments for hirsutism. The physical examination should include observation to determine the presence and degree of hirsutism and to detect signs suggestive of the specific etiology. A pelvic examination should be performed with close attention to signs of androgenization (e.g., clitoromegaly) or abdominal or pelvic masses.

FIGURE 2.

Suggested approach to evaluating hirsutism. (DHEAS = dehydroepiandrosterone sulfate; FG = Ferriman-Gallwey.)

Adapted with permission from Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):377, with additional information from references 6, 14, and 21.


FIGURE 2.

Suggested approach to evaluating hirsutism. (DHEAS = dehydroepiandrosterone sulfate; FG = Ferriman-Gallwey.)

Adapted with permission from Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):377, with additional information from references 6, 14, and 21.

Women with hirsutism and menstrual dysfunction, infertility, or any physical examination findings suggestive of endocrine disorders should undergo further hormonal workup.6 Rapid development of hirsutism, late onset, progression despite therapy, or signs of virilization may indicate an androgen-secreting tumor.14 In contrast, benign etiologies typically present with peripubertal onset, slow progression, family history of hyperandrogenism, and, rarely, signs of virilization.

Clinical practice guidelines suggest testing for elevated androgen levels in women with an abnormal hirsutism score.6,14,22 The degree of hirsutism does not necessarily correlate with the testosterone level. Free testosterone is the biologically active component of serum testosterone; however, there is considerable variability in measurements reported by various assays, particularly at low levels.2224 Measurement of free testosterone is more accurate with equilibrium dialysis methods used by specialty laboratories. Unless this technique is available, the test is not reliable.

Other endocrine causes of hirsutism such as hypothyroidism and hyperprolactinemia can be excluded by serum thyroid studies and measurement of prolactin, which is particularly relevant in patients with other signs and symptoms consistent with these conditions. Women with hyperandrogenism or those with hirsutism who are at high risk (because of family history or race/ethnicity) warrant further workup with measurement of early morning 17-hydroxyprogesterone and DHEAS to screen for adrenal hyperandrogenism. Assessment for Cushing syndrome or acromegaly is warranted in women with features of these conditions. Pelvic ultrasonography is indicated to identify ovarian lesions in women with features suggestive of androgen-secreting tumors or to determine ovarian morphology.

Treatment

If bothersome hirsutism persists despite cosmetic measures (e.g., shaving, plucking, waxing), pharmacologic treatment should be initiated (Table 213,22,2531), followed by direct hair removal methods if pharmacologic treatment does not yield satisfactory results.6 Pharmacologic therapy should be avoided if the patient is pregnant or trying to become pregnant. Lifestyle changes should be encouraged for patients with obesity, including those with PCOS. Referral to a dermatologist may be considered for intractable cases.

 Enlarge     Print

TABLE 2.

Medications for the Treatment of Hirsutism

MedicationDosageAdverse effectsCommentsU.S. Food and Drug Administration pregnancy risk

Combined oral contraceptives

One tablet daily

Headache, nausea

First-line agents; may be used in combination with antiandrogens

Accidental use in pregnancy is low risk; may decrease lactation

Eflornithine (Vaniqa)

Apply topically twice daily

Acne, local irritation

Expensive

Safety risks unknown

Finasteride (Propecia)

2.5 mg daily

Decreased libido

Additive benefit when used with spironolactone

High risk of feminization of male fetus

Glucocorticoids

Prednisone: 5 mg twice daily

Adrenal suppression, bone density loss, weight gain

Use in patients with congenital adrenal hyperplasia

Increased risk of growth retardation and cleft palate, especially if used in first trimester

Leuprolide (Lupron)

3.75 mg intramuscularly monthly

Bone density loss, hot flashes, vaginal dryness

Consider using in conjunction with combined oral contraceptives

High risk of fetal harm

Spironolactone

100 to 200 mg daily

Breast tenderness, hyperkalemia, irregular menses

Risk of breast adenomas in murine testing

Increased risk of spontaneous abortion and feminization of male fetus


Information from references 13, 22, and 2531.

TABLE 2.

Medications for the Treatment of Hirsutism

MedicationDosageAdverse effectsCommentsU.S. Food and Drug Administration pregnancy risk

Combined oral contraceptives

One tablet daily

Headache, nausea

First-line agents; may be used in combination with antiandrogens

Accidental use in pregnancy is low risk; may decrease lactation

Eflornithine (Vaniqa)

Apply topically twice daily

Acne, local irritation

Expensive

Safety risks unknown

Finasteride (Propecia)

2.5 mg daily

Decreased libido

Additive benefit when used with spironolactone

High risk of feminization of male fetus

Glucocorticoids

Prednisone: 5 mg twice daily

Adrenal suppression, bone density loss, weight gain

Use in patients with congenital adrenal hyperplasia

Increased risk of growth retardation and cleft palate, especially if used in first trimester

Leuprolide (Lupron)

3.75 mg intramuscularly monthly

Bone density loss, hot flashes, vaginal dryness

Consider using in conjunction with combined oral contraceptives

High risk of fetal harm

Spironolactone

100 to 200 mg daily

Breast tenderness, hyperkalemia, irregular menses

Risk of breast adenomas in murine testing

Increased risk of spontaneous abortion and feminization of male fetus


Information from references 13, 22, and 2531.

PHARMACOLOGIC TREATMENT

Combined oral contraceptives should be used as initial therapy for hirsutism in women who are not trying to conceive.6,22,25,26,32 These drugs suppress luteinizing hormone secretion, which decreases ovarian androgen production. They also stimulate production of sex hormone–binding globulin, thereby lowering serum free androgen levels. A recent meta-analysis showed that combined oral contraceptives decrease hirsutism scores, but because improvement in patient distress was not reported it is not known whether these differences are clinically meaningful.32 Low-androgen combined oral contraceptives containing desogestrel and drospirenone improved hirsutism scores slightly more than other formulations, but the difference was small and probably not clinically important.26

If combined oral contraceptives are contraindicated or ineffective, the antiandrogens spironolactone, finasteride (Propecia), or dutasteride (Avodart) may be considered.6,22,27,28,32,33 The antiandrogen flutamide should be avoided because of hepatotoxicity. Antiandrogens are teratogenic and must be avoided in pregnancy. They seem to confer an additive benefit when used with combined oral contraceptives. For women with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, glucocorticoids are effective for the treatment of hirsutism.13 However, they are much less effective in women with nonclassic congenital adrenal hyperplasia and should be used only if trials of combined oral contraceptives and antiandrogen therapy are ineffective.29

Gonadotropin-releasing hormone agnoists such as leuprolide (Lupron) have been beneficial in reducing hirsutism in patients with ovarian hyperandrogenism. However, they cause severe hypoestrogenism and bone loss, and their use is generally not recommended except in patients with severe hyperandrogenism, in whom combined oral contraceptives and antiandrogens are ineffective.6,34 Insulin-lowering medications such as metformin and pioglitazone (Actos) are widely used in the treatment of PCOS, but they are not effective for the treatment of hirsutism.6,30,32

The ornithine decarboxylase inhibitor eflornithine (Vaniqa) can be used as topical therapy for excessive facial hair. Patients should expect noticeable improvement in approximately six to eight weeks.35 Eflornithine is safe when combined with other therapies.

HAIR REMOVAL METHODS

Numerous hair removal methods may be used to treat hirsutism.6 Shaving is inexpensive and effective but must be done frequently. Chemical depilatory agents can be used to dissolve the hair but may irritate the skin and cause dermatitis. Epilation by plucking or waxing is also effective but is painful and can result in scarring, folliculitis, and hyperpigmentation.

If patients desire a more permanent solution, photoepilation or electrolysis can be considered.6 Although electrolysis is effective, it can also be painful, time consuming, and impractical for removing hair over large areas of skin. Because of these limitations, photoepilation has become the most popular procedure for long-term hair removal. Photoepilation destroys pigmented terminal hair follicles through thermal damage from one of four types of lasers, based on the patient's hair color and skin pigmentation. Photoepilation is not entirely effective; trials have shown hair reduction of 40% to 80%, depending on the type of laser used and the number of treatments provided.36 Despite its limitations, photoepilation is the preferred treatment for permanent hair removal. It is up to 60 times faster to perform than electrolysis and seems to be more effective in most patients. The exceptions are blonde and white-haired women, in whom electrolysis is a better option.21

This article updates previous articles on this topic by Bode, et al.,13 and by Hunter and Carek.37

Data Sources: A PubMed search was completed in Clinical Queries using the key terms hirsutism, hypertrichosis, hair removal, and polycystic ovarian syndrome. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Search date: March 16, 2018.

The Authors

show all author info

ERIC MATHESON, MD, MS, is a transitional year residency director and associate professor of family medicine at the Medical University of South Carolina, Charleston....

JENNIFER BAIN, MD, is a women's health education director, clinical services director, and clinical associate professor of family medicine at the Medical University of South Carolina.

Address correspondence to Eric Matheson, MD, MS, 9228 Medical Plaza Dr., Charleston, SC 29406 (email: matheson@musc.edu). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

References

show all references

1. Barth JH, Catalan J, Cherry CA, et al. Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res. 1993;37(6):615–619....

2. Sonino N, Fava GA, Mani E, et al. Quality of life of hirsute women. Post-grad Med J. 1993;69(809):186–189.

3. Ekbäck M, Wijma K, Benzein E. “It is always on my mind”: women's experiences of their bodies when living with hirsutism. Health Care Women Int. 2009;30(5):358–372.

4. Keegan A, Liao LM, Boyle M. ‘Hirsutism’: a psychological analysis. J Health Psychol. 2003;8(3):327–345.

5. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101(5 pt 1):995–1007.

6. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233–1257.

7. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341(7):491–497.

8. Araújo R, Fernandes M, Cavaco-Paulo A, et al. Biology of human hair: know your hair to control it. Adv Biochem Eng Biotechnol. 2011;125:121–143.

9. Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314–328.

10. Ebling FJ. Hair follicles and associated glands as androgen targets. Clin Endocrinol Metab. 1986;15(2):319–339.

11. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447.

12. Hatch R, Rosenfield RL, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140(7):815–830.

13. Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):373–380.

14. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society [published correction appears in Hum Reprod Update. 2013;19(2):207]. Hum Reprod Update. 2012;18(2):146–170.

15. Mihailidis J, Dermesropian R, Taxel P, et al. Endocrine evaluation of hirsutism. Int J Womens Dermatol. 2017;3(1 suppl):S6–S10.

16. Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovarian syndrome—part 1. Endocr Pract. 2015;21(11):1291–1300.

17. Reingold SB, Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol. 1987;123(2):209–212.

18. Hohl A, Ronsoni MF, Oliveira MD. Hirsutism: diagnosis and treatment. Arq Bras Endocrinol Metabol. 2014;58(2):97–107.

19. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329(19):1383–1388.

20. Loriaux DL. An approach to the patient with hirsutism. J Clin Endocrinol Metab. 2012;97(9):2957–2968.

21. Mimoto MS, Oyler JL, Davis AM. Evaluation and treatment of hirsutism in premenopausal women. JAMA. 2018;319(15):1613–1614.

22. Liu K, Motan T, Claman P. No. 350—hirsutism: evaluation and treatment. J Obstet Gynaecol Can. 2017;39(11):1054–1068.

23. Goldman AL, Bhasin S, Wu FC, et al. A reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38(4):302–324.

24. Korkidakis AK, Reid RL. Testosterone in women: measurement and therapeutic use. J Obstet Gynaecol Can. 2017;39(3):124–130.

25. van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;(4):CD010334.

26. Porcile A, Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril. 1991;55(5):877–881.

27. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999;84(4):1304–1310.

28. Bayram F, Müderris II, Güven M, et al. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol. 2002;147(4):467–471.

29. Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab. 1990;70(3):642–646.

30. Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93(4):1135–1142.

31. Speiser PW, Azziz R, Baskin LS, et al.; Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2010;95(11):5137]. J Clin Endocrinol Metab. 2010;95(9):4133–4160.

32. Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018;103(4):1258–1264.

33. Keleştimur F, Everest H, Unlühizarci K, et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol. 2004;150(3):351–354.

34. Carr BR, Breslau NA, Givens C, et al. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab. 1995;80(4):1169–1178.

35. Wolf JE Jr, Shander D, Huber F, et al.; Eflornithine HCl Study Group. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol. 2007;46(1):94–98.

36. Sadighha A, Mohaghegh Zahed G. Meta-analysis of hair removal laser trials. Lasers Med Sci. 2009;24(1):21–25.

37. Hunter MH, Carek PJ. Evaluation and treatment of women with hirsutism. Am Fam Physician. 2003;67(12):2565–2572.

 

 

Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2020

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article